Functional and Pharmacological Characterization of the Natriuretic Peptide-Dependent Lipolytic Pathway in Human Fat Cells
Open Access
- 21 November 2003
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 308 (3), 984-992
- https://doi.org/10.1124/jpet.103.060913
Abstract
A lipolytic pathway involving natriuretic peptides has recently been discovered in human fat cells. Its functional characteristics and the interactions of the atrial natriuretic peptide (ANP)-induced effects with adrenergic and insulin pathways were studied. Characterization of the action of ANP antagonists, i.e., A71915, anantin, S-28-Y (Ser-28-Tyr, a synthesized peptide), and HS-142-1 (a microbial polysaccharide), was performed. Lipolytic assays and intracellular cGMP and cAMP determinations were performed on isolated fat cells. Cell membranes were used for binding studies. At low concentrations ANP and isoproterenol [β-adrenergic receptor (β-AR) agonist] exerted additive lipolytic effects. The α2-AR pathway did not interfere with that of ANP. Lipolytic effects of ANP were unaltered by a 2-h pretreatment of fat cells with insulin, whereas β-AR-induced lipolysis was reduced. Homologous desensitization occurred for ANP-dependent lipolytic pathways. Dendroapsis natriuretic peptide exhibited a similar maximal effect but a 10-fold higher lipolytic potency than ANP and mini-ANP (the shortest form of ANP). The antagonist A71915 exhibited competitive antagonistic properties with a pA2 value of 7.51. Anantin displayed noncompetitive antagonism and exerted an inhibitory action on basal and β-adrenergic receptor-induced lipolytic response. S-28-Y exhibited antagonist potencies toward ANP-induced lipolysis and behaved as a partial lipolytic agonist with a lower pD2 value (7.4 ± 0.2) than ANP (9.4 ± 0.3). HS-142-1 exerted the weakest antagonistic effects. The results demonstrate that ANP-dependent effects do not interfere with β- and α2-adrenergic pathways in human fat cells. They are unaffected by insulin pretreatments of fat cells but undergo desensitization. In the search of potent and specific natriuretic peptide receptor-A antagonist, in the human fat cell, A71915 was the only reliable one found.Keywords
This publication has 32 references indexed in Scilit:
- Allotopic antagonism of the non-peptide atrial natriuretic peptide (ANP) antagonist HS-142-1 on natriuretic peptide receptor NPR-ABiochemical Journal, 2002
- Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese womenInternational Journal of Obesity, 2002
- Role of the sympathoadrenergic system in adipose tissue metabolism during exercise in humansThe Journal of Physiology, 2001
- Importance of Phosphodiesterase 3 for the Lipolytic Response in Adipose Tissue During Insulin-Induced Hypoglycemia in Normal ManHormone and Metabolic Research, 1998
- Gender Differences in Adremergic Regulation of Lipid Mobilization During ExerciseInternational Journal of Sports Medicine, 1996
- Metabolic Effects of Atenolol and Doxazosin in Healthy Volunteers During Prolonged Physical ExerciseJournal of Cardiovascular Pharmacology, 1995
- Tertatolol Potentiates Exercise-Induced Atrial Natriuretic Peptide Release by Increasing Atrial Diameter in Healthy SubjectsCardiology, 1993
- Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptorBiochemical and Biophysical Research Communications, 1991
- Synthesis and biological property of .ALPHA.-human atrial natriuretic peptide analogs with a constrained or stereochemically modified cyclic moiety.CHEMICAL & PHARMACEUTICAL BULLETIN, 1990
- Human adipose tissue blood flow during prolonged exercise, III. Effect of F-adrenergic blockade, nicotinic acid and glucose infusionScandinavian Journal of Clinical and Laboratory Investigation, 1981